Guggenheim Reaffirms Buy Rating for Bristol Myers Squibb with $72 Target

Guggenheim has maintained its "Buy" rating for Bristol Myers Squibb (BMY), setting a price target of $72 per share. This target implies a significant potential upside of approximately 24.8% from the stock's current trading levels. The reaffirmation comes despite the pharmaceutical giant reporting earnings per share (EPS) that fell short of market expectations in its most recent quarter. Furthermore, the company's financial guidance for the 2026 fiscal year was lower than what many analysts had previously estimated. Guggenheim's stance reflects a belief in the stock's long-term value proposition amidst short-term financial volatility and conservative guidance. While the firm remains bullish, the broader market sentiment continues to weigh the company's revised growth outlook against its current valuation.